The DOI matches its Crossref record; 113 of the 113 references it cites were found in a registry or an index.
PTEN: a new guardian of the genome
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Chung, J.-H., Ginn-Pease, M. E., & Eng, C. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0124 · Cited by 164
Retractedp53, the cellular gatekeeper for growth and division
Levine, A. J. (1997) · Cell · doi:10.1016/s0092-8674(00)81871-1 · Cited by 7,693
Vogelstein, B., Lane, D., & Levine, A. J. (2000) · Nature · doi:10.1038/35042675 · Cited by 6,607 · cited 2×
“Tumor suppressor network: p53, PTEN and beyond p53 is the most frequently mutated gene in human cancers (Vogelstein et al., 2000; Levine et al., 2004).”
BackgroundLane, D. P. (1992) · Nature · doi:10.1038/358015a0 · Cited by 5,138
Li, J., Yen, C., Liaw, D., Podsypanina, K., Bose, S., Wang, S. I., Puc, J., Miliaresis, C., Rodgers, L., McCombie, R., et al. (1997) · Science · doi:10.1126/science.275.5308.1943 · Cited by 4,785
Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours
Donehower, L. A., Harvey, M., Slagle, B. L., McArthur, M. J., Montgomery, C. A., Butel, J. S., & Bradley, A. (1992) · Nature · doi:10.1038/356215a0 · Cited by 4,649
Germ Line p53 Mutations in a Familial Syndrome of Breast Cancer, Sarcomas, and Other Neoplasms
Malkin, D., Li, F. P., Strong, L. C., Fraumeni, J. F., Nelson, C. E., Kim, D. H., Kassel, J., Gryka, M. A., Bischoff, F. Z., Tainsky, M. A., et al. (1990) · Science · doi:10.1126/science.1978757 · Cited by 3,765
p21 is a universal inhibitor of cyclin kinases
Xiong, Y., Hannon, G. J., Zhang, H., Casso, D., Kobayashi, R., & Beach, D. (1993) · Nature · doi:10.1038/366701a0 · Cited by 3,368
Maehama, T., & Dixon, J. E. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.22.13375 · Cited by 3,104
Kastan, M. B., Zhan, Q., El-Deiry, W. S., Carrier, F., Jacks, T., Walsh, W. V., Plunkett, B. S., Vogelstein, B., & Fornace, A. J. (1992) · Cell · doi:10.1016/0092-8674(92)90593-2 · Cited by 3,047 · cited 1×
“…factor that regulates target genes (Levine, 1997). p53 controls cellcycle progression, apoptosis and genomic stability (Yonish-Rouach et al., 1991; Kastan et al., 1992; Livingstone et al., 1992; Yin et al., 1992; Lowe et al., Oncogene 1993; Tlsty et al., 1994). p53 is the first to be proposed as…”
Background
Research works printed but not linked: 10
- Gildea JJ, Herlevsen M, Harding MA, Gulding KM, Moskaluk CA, Frierson HF et al. (2004). PTEN can inhibit in vitro organotypic and in vivo orthotopic invasion of human bladder cancer cells even in the absence of its lipid phosphatase activity. Oncogene 23: 6788–6797. · doi:10.1038/sj.onc.1207599
- Iida S, Nakamura Y, Fujii H, Kimura M, Moriwaki K . (1998). A heterozygous germline mutation of the PTEN/MMAC1 gene in a patient with Cowden disease. Int J Mol Med 1: 565–568.
- Iida S, Ono A, Sayama K, Hamaguchi T, Fujii H, Nakajima H et al. (2000). Accelerated decline of blood glucose after intravenous glucose injection in a patient with Cowden disease having a heterozygous germline mutation of the PTEN/MMAC1 gene. Anticancer Res 20: 1901–1904.
- Kanaseki T, Torigoe T, Hirohashi Y, Hirai I, Himi T, Sato N . (2002). Identification of germline mutation of PTEN gene and analysis of apoptosis resistance of the lymphocytes in a patient with Cowden disease. Pathobiology 70: 34–39. · doi:10.1159/000066001
- Kang-Park S, Lee YI, Lee YI . (2003). PTEN modulates insulin-like growth factor II (IGF-II)-mediated signaling; the protein phosphatase activity of PTEN downregulates IGF-II expression in hepatoma cells. FEBS Lett 545: 203–208. · DOI
- Koul A, Willen R, Bendahl PO, Nilbert M, Borg A . (2002). Distinct sets of gene alterations in endometrial carcinoma implicate alternate modes of tumorigenesis. Cancer 94: 2369–2379. · doi:10.1002/cncr.10498
- Okumura K, Zhao M, DePinho RA, Furnari FB, Cavenee WK . (2005). PTEN: a novel anti-oncogenic function independent of phosphatase activity. Cell Cycle 4: 540–542. · doi:10.4161/cc.4.4.1614
- Shin KH, Kim JM, Rho KS, Park KH, Oh JE, Min BM . (2002). Inactivation of the PTEN gene by mutation, exonic deletion, and loss of transcript in human oral squamous cell carcinomas. Int J Oncol 21: 997–1001.
- Tlsty TD, White A, Livanos E, Sage M, Roelofs H, Briot A et al. (1994). Genomic integrity and the genetics of cancer. Cold Spring Harb Symp Quant Biol 59: 265–275. · doi:10.1101/sqb.1994.059.01.031
- Weinberg RA . (1992). The retinoblastoma gene and gene product. Cancer Surv 12: 43–57.
Cited by
Hallmarks of Cellular Senescence
Hernandez-Segura, A., Nehme, J., & Demaria, M. (2018) · Trends in Cell Biology · doi:10.1016/j.tcb.2018.02.001 · Cited by 2,605
Molecular Basis of Colorectal Cancer
Markowitz, S. D., & Bertagnolli, M. M. (2009) · New England Journal of Medicine · doi:10.1056/nejmra0804588 · Cited by 2,052
How does p53 induce apoptosis and how does this relate to p53-mediated tumour suppression
Aubrey, B. J., Kelly, G. L., Janic, A., Herold, M. J., & Strasser, A. (2018) · Cell Death & Differentiation · doi:10.1038/cdd.2017.169 · Cited by 1,395
A compendium of mutational cancer driver genes
Martínez-Jiménez, F., Muiños, F., Sentís, I., Deu-Pons, J., Reyes-Salazar, I., Arnedo-Pac, C., Mularoni, L., Pich, O., Bonet, J., Kranas, H., et al. (2020) · Nature Reviews Cancer · doi:10.1038/s41568-020-0290-x · Cited by 1,296
Dual-specificity phosphatases: critical regulators with diverse cellular targets
Patterson, K. I., Brummer, T., O'brien, P. M., & Daly, R. J. (2009) · Biochemical Journal · doi:10.1042/bj20082234 · Cited by 744
Metadata
- Authors
- Yin, Y., & Shen, W. H.
- Venue
- Oncogene
- Published
- 2008-09-15
- Volume
- 27
- Issue
- 41
- Pages
- 5443-5453
- ISSN
- 0950-9232 (ISSN-L)
- 1476-5594
- OpenAlex
- W2091338477
- Cited by
- 388
- References
- 113
- FWCI
- 11.04
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: PTEN: a new guardian of the genome. https://app.cochat.ai/papers/10.1038/onc.2008.241
- The paper
- Yin, Y., & Shen, W. H. (2008). PTEN: a new guardian of the genome. Oncogene. https://doi.org/10.1038/onc.2008.241
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
